APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pre-Exposure Prophylaxis

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pre-Exposure Prophylaxis Market Outlook and Growth Opportunities 2026

Report ID 174027810430 December 2025197 pages

Choose your research edition.

Industry ResearchPre-Exposure Prophylaxis Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Pre-Exposure Prophylaxis Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal Pre-Exposure Prophylaxis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pre-Exposure Prophylaxis Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Pre-Exposure Prophylaxis Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Pre-Exposure Prophylaxis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pre-Exposure Prophylaxis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pre-Exposure Prophylaxis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pre-Exposure Prophylaxis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pre-Exposure Prophylaxis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pre-Exposure Prophylaxis market include Gilead Sciences, Lupin, Strides Pharma Science and Teva Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pre-Exposure Prophylaxis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pre-Exposure Prophylaxis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pre-Exposure Prophylaxis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pre-Exposure Prophylaxis market size, projected growth trends, production technologies, key applications, and end-use industries.

Pre-Exposure Prophylaxis Segment by Company

Gilead Sciences

Lupin

Strides Pharma Science

Teva Pharmaceuticals

Pre-Exposure Prophylaxis Segment by Type

Truvada

Discovy

Pre-Exposure Prophylaxis Segment by Application

Adult

Adolescent

Pre-Exposure Prophylaxis Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Pre-Exposure Prophylaxis status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pre-Exposure Prophylaxis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pre-Exposure Prophylaxis significant trends, drivers, influence factors in global and regions.

6. To analyze Pre-Exposure Prophylaxis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pre-Exposure Prophylaxis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pre-Exposure Prophylaxis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pre-Exposure Prophylaxis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pre-Exposure Prophylaxis market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pre-Exposure Prophylaxis industry.

Chapter 3: Detailed analysis of Pre-Exposure Prophylaxis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pre-Exposure Prophylaxis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pre-Exposure Prophylaxis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pre-Exposure Prophylaxis Industry Trends Table 2. Pre-Exposure Prophylaxis Industry Drivers Table 3. Pre-Exposure Prophylaxis Industry Opportunities and Challenges Table 4. Pre-Exposure Prophylaxis Industry Restraints Table 5. Global Pre-Exposure Prophylaxis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pre-Exposure Prophylaxis Revenue Share by Company (2021-2026) Table 7. Global Pre-Exposure Prophylaxis Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Pre-Exposure Prophylaxis Sales Volume Share by Company (2021-2026) Table 9. Global Pre-Exposure Prophylaxis Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pre-Exposure Prophylaxis Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pre-Exposure Prophylaxis Key Company Manufacturing Base & Headquarters Table 12. Global Pre-Exposure Prophylaxis Company, Product Type & Application Table 13. Global Pre-Exposure Prophylaxis Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pre-Exposure Prophylaxis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Truvada Table 18. Significant Companies of Discovy Table 19. Global Pre-Exposure Prophylaxis Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Pre-Exposure Prophylaxis Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Pre-Exposure Prophylaxis Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Pre-Exposure Prophylaxis Sales Volume Share by Type (2021-2026) Table 23. Global Pre-Exposure Prophylaxis Sales Volume Share by Type (2027-2032) Table 24. Global Pre-Exposure Prophylaxis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Pre-Exposure Prophylaxis Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Pre-Exposure Prophylaxis Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Pre-Exposure Prophylaxis Sales Value Share by Type (2021-2026) Table 28. Global Pre-Exposure Prophylaxis Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Adult Table 30. Significant Companies of Adolescent Table 31. Global Pre-Exposure Prophylaxis Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Pre-Exposure Prophylaxis Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Pre-Exposure Prophylaxis Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Pre-Exposure Prophylaxis Sales Volume Share by Application (2021-2026) Table 35. Global Pre-Exposure Prophylaxis Sales Volume Share by Application (2027-2032) Table 36. Global Pre-Exposure Prophylaxis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Pre-Exposure Prophylaxis Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Pre-Exposure Prophylaxis Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Pre-Exposure Prophylaxis Sales Value Share by Application (2021-2026) Table 40. Global Pre-Exposure Prophylaxis Sales Value Share by Application (2027-2032) Table 41. Global Pre-Exposure Prophylaxis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Pre-Exposure Prophylaxis Sales by Region (2021-2026) & (K Units) Table 43. Global Pre-Exposure Prophylaxis Sales Market Share by Region (2021-2026) Table 44. Global Pre-Exposure Prophylaxis Sales by Region (2027-2032) & (K Units) Table 45. Global Pre-Exposure Prophylaxis Sales Market Share by Region (2027-2032) Table 46. Global Pre-Exposure Prophylaxis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Pre-Exposure Prophylaxis Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Pre-Exposure Prophylaxis Sales Value Share by Region (2021-2026) Table 49. Global Pre-Exposure Prophylaxis Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Pre-Exposure Prophylaxis Sales Value Share by Region (2027-2032) Table 51. Global Pre-Exposure Prophylaxis Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Pre-Exposure Prophylaxis Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Pre-Exposure Prophylaxis Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Pre-Exposure Prophylaxis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Pre-Exposure Prophylaxis Sales by Country (2021-2026) & (K Units) Table 56. Global Pre-Exposure Prophylaxis Sales Market Share by Country (2021-2026) Table 57. Global Pre-Exposure Prophylaxis Sales by Country (2027-2032) & (K Units) Table 58. Global Pre-Exposure Prophylaxis Sales Market Share by Country (2027-2032) Table 59. Global Pre-Exposure Prophylaxis Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Pre-Exposure Prophylaxis Sales Value Market Share by Country (2021-2026) Table 61. Global Pre-Exposure Prophylaxis Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Pre-Exposure Prophylaxis Sales Value Market Share by Country (2027-2032) Table 63. Gilead Sciences Company Information Table 64. Gilead Sciences Business Overview Table 65. Gilead Sciences Pre-Exposure Prophylaxis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Gilead Sciences Pre-Exposure Prophylaxis Product Portfolio Table 67. Gilead Sciences Recent Development Table 68. Lupin Company Information Table 69. Lupin Business Overview Table 70. Lupin Pre-Exposure Prophylaxis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Lupin Pre-Exposure Prophylaxis Product Portfolio Table 72. Lupin Recent Development Table 73. Strides Pharma Science Company Information Table 74. Strides Pharma Science Business Overview Table 75. Strides Pharma Science Pre-Exposure Prophylaxis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Strides Pharma Science Pre-Exposure Prophylaxis Product Portfolio Table 77. Strides Pharma Science Recent Development Table 78. Teva Pharmaceuticals Company Information Table 79. Teva Pharmaceuticals Business Overview Table 80. Teva Pharmaceuticals Pre-Exposure Prophylaxis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Teva Pharmaceuticals Pre-Exposure Prophylaxis Product Portfolio Table 82. Teva Pharmaceuticals Recent Development Table 83. Key Raw Materials Table 84. Raw Materials Key Suppliers Table 85. Pre-Exposure Prophylaxis Distributors List Table 86. Pre-Exposure Prophylaxis Customers List Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Pre-Exposure Prophylaxis Product Image Figure 2. Global Pre-Exposure Prophylaxis Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pre-Exposure Prophylaxis Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pre-Exposure Prophylaxis Sales (2021-2032) & (K Units) Figure 5. Global Pre-Exposure Prophylaxis Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pre-Exposure Prophylaxis Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Truvada Image Figure 10. Discovy Image Figure 11. Global Pre-Exposure Prophylaxis Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Pre-Exposure Prophylaxis Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Pre-Exposure Prophylaxis Sales Volume Share by Type (2021-2032) Figure 14. Global Pre-Exposure Prophylaxis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Pre-Exposure Prophylaxis Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Pre-Exposure Prophylaxis Sales Value Share by Type (2021-2032) Figure 17. Adult Image Figure 18. Adolescent Image Figure 19. Global Pre-Exposure Prophylaxis Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Pre-Exposure Prophylaxis Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Pre-Exposure Prophylaxis Sales Volume Share by Application (2021-2032) Figure 22. Global Pre-Exposure Prophylaxis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Pre-Exposure Prophylaxis Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Pre-Exposure Prophylaxis Sales Value Share by Application (2021-2032) Figure 25. Global Pre-Exposure Prophylaxis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Pre-Exposure Prophylaxis Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Pre-Exposure Prophylaxis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Pre-Exposure Prophylaxis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Pre-Exposure Prophylaxis Sales Value (2021-2032) & (US$ Million) Figure 30. North America Pre-Exposure Prophylaxis Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Pre-Exposure Prophylaxis Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Pre-Exposure Prophylaxis Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Pre-Exposure Prophylaxis Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Pre-Exposure Prophylaxis Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Pre-Exposure Prophylaxis Sales Value (2021-2032) & (US$ Million) Figure 36. South America Pre-Exposure Prophylaxis Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Pre-Exposure Prophylaxis Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Pre-Exposure Prophylaxis Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Pre-Exposure Prophylaxis Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Pre-Exposure Prophylaxis Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Truvada
  • Discovy
Applications
  • Adult
  • Adolescent
Companies covered
  • Gilead Sciences
  • Lupin
  • Strides Pharma Science
  • Teva Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pre-Exposure Prophylaxis Sales Value (2021-2032)
  4. 1.2.2 Global Pre-Exposure Prophylaxis Sales Volume (2021-2032)
  5. 1.2.3 Global Pre-Exposure Prophylaxis Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pre-Exposure Prophylaxis Market Dynamics
  1. 2.1 Pre-Exposure Prophylaxis Industry Trends
  2. 2.2 Pre-Exposure Prophylaxis Industry Drivers
  3. 2.3 Pre-Exposure Prophylaxis Industry Opportunities and Challenges
  4. 2.4 Pre-Exposure Prophylaxis Industry Restraints
3 Pre-Exposure Prophylaxis Market by Company
  1. 3.1 Global Pre-Exposure Prophylaxis Company Revenue Ranking in 2025
  2. 3.2 Global Pre-Exposure Prophylaxis Revenue by Company (2021-2026)
  3. 3.3 Global Pre-Exposure Prophylaxis Sales Volume by Company (2021-2026)
  4. 3.4 Global Pre-Exposure Prophylaxis Average Price by Company (2021-2026)
  5. 3.5 Global Pre-Exposure Prophylaxis Company Ranking (2024-2026)
  6. 3.6 Global Pre-Exposure Prophylaxis Company Manufacturing Base and Headquarters
  7. 3.7 Global Pre-Exposure Prophylaxis Company Product Type and Application
  8. 3.8 Global Pre-Exposure Prophylaxis Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pre-Exposure Prophylaxis Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pre-Exposure Prophylaxis Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pre-Exposure Prophylaxis Market by Type
  1. 4.1 Pre-Exposure Prophylaxis Type Introduction
  2. 4.1.1 Truvada
  3. 4.1.2 Discovy
  4. 4.2 Global Pre-Exposure Prophylaxis Sales Volume by Type
  5. 4.2.1 Global Pre-Exposure Prophylaxis Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pre-Exposure Prophylaxis Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Pre-Exposure Prophylaxis Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Pre-Exposure Prophylaxis Sales Value by Type
  9. 4.3.1 Global Pre-Exposure Prophylaxis Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pre-Exposure Prophylaxis Sales Value by Type (2021-2032)
  11. 4.3.3 Global Pre-Exposure Prophylaxis Sales Value Share by Type (2021-2032)
5 Pre-Exposure Prophylaxis Market by Application
  1. 5.1 Pre-Exposure Prophylaxis Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Adolescent
  4. 5.2 Global Pre-Exposure Prophylaxis Sales Volume by Application
  5. 5.2.1 Global Pre-Exposure Prophylaxis Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pre-Exposure Prophylaxis Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Pre-Exposure Prophylaxis Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Pre-Exposure Prophylaxis Sales Value by Application
  9. 5.3.1 Global Pre-Exposure Prophylaxis Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Pre-Exposure Prophylaxis Sales Value by Application (2021-2032)
  11. 5.3.3 Global Pre-Exposure Prophylaxis Sales Value Share by Application (2021-2032)
6 Pre-Exposure Prophylaxis Regional Sales and Value Analysis
  1. 6.1 Global Pre-Exposure Prophylaxis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pre-Exposure Prophylaxis Sales by Region (2021-2032)
  3. 6.2.1 Global Pre-Exposure Prophylaxis Sales by Region: 2021-2026
  4. 6.2.2 Global Pre-Exposure Prophylaxis Sales by Region (2027-2032)
  5. 6.3 Global Pre-Exposure Prophylaxis Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pre-Exposure Prophylaxis Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pre-Exposure Prophylaxis Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pre-Exposure Prophylaxis Sales Value by Region (2027-2032)
  9. 6.5 Global Pre-Exposure Prophylaxis Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pre-Exposure Prophylaxis Sales Value (2021-2032)
  12. 6.6.2 North America Pre-Exposure Prophylaxis Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pre-Exposure Prophylaxis Sales Value (2021-2032)
  15. 6.7.2 Europe Pre-Exposure Prophylaxis Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pre-Exposure Prophylaxis Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pre-Exposure Prophylaxis Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pre-Exposure Prophylaxis Sales Value (2021-2032)
  21. 6.9.2 South America Pre-Exposure Prophylaxis Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pre-Exposure Prophylaxis Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pre-Exposure Prophylaxis Sales Value Share by Country, 2025 VS 2032
7 Pre-Exposure Prophylaxis Country-level Sales and Value Analysis
  1. 7.1 Global Pre-Exposure Prophylaxis Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pre-Exposure Prophylaxis Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pre-Exposure Prophylaxis Sales by Country (2021-2032)
  4. 7.3.1 Global Pre-Exposure Prophylaxis Sales by Country (2021-2026)
  5. 7.3.2 Global Pre-Exposure Prophylaxis Sales by Country (2027-2032)
  6. 7.4 Global Pre-Exposure Prophylaxis Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pre-Exposure Prophylaxis Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pre-Exposure Prophylaxis Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pre-Exposure Prophylaxis Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pre-Exposure Prophylaxis Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pre-Exposure Prophylaxis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Gilead Sciences
  2. 8.1.1 Gilead Sciences Company Information
  3. 8.1.2 Gilead Sciences Business Overview
  4. 8.1.3 Gilead Sciences Pre-Exposure Prophylaxis Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Gilead Sciences Pre-Exposure Prophylaxis Product Portfolio
  6. 8.1.5 Gilead Sciences Recent Developments
  7. 8.2 Lupin
  8. 8.2.1 Lupin Company Information
  9. 8.2.2 Lupin Business Overview
  10. 8.2.3 Lupin Pre-Exposure Prophylaxis Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Lupin Pre-Exposure Prophylaxis Product Portfolio
  12. 8.2.5 Lupin Recent Developments
  13. 8.3 Strides Pharma Science
  14. 8.3.1 Strides Pharma Science Company Information
  15. 8.3.2 Strides Pharma Science Business Overview
  16. 8.3.3 Strides Pharma Science Pre-Exposure Prophylaxis Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Strides Pharma Science Pre-Exposure Prophylaxis Product Portfolio
  18. 8.3.5 Strides Pharma Science Recent Developments
  19. 8.4 Teva Pharmaceuticals
  20. 8.4.1 Teva Pharmaceuticals Company Information
  21. 8.4.2 Teva Pharmaceuticals Business Overview
  22. 8.4.3 Teva Pharmaceuticals Pre-Exposure Prophylaxis Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Teva Pharmaceuticals Pre-Exposure Prophylaxis Product Portfolio
  24. 8.4.5 Teva Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pre-Exposure Prophylaxis Value Chain Analysis
  2. 9.1.1 Pre-Exposure Prophylaxis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pre-Exposure Prophylaxis Sales Mode & Process
  6. 9.2 Pre-Exposure Prophylaxis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pre-Exposure Prophylaxis Distributors
  9. 9.2.3 Pre-Exposure Prophylaxis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst